Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
15 participants
INTERVENTIONAL
2025-08-21
2026-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Rituximab in the Treatment of Graves' Disease
NCT00150111
Allogeneic Anti-CD19 CAR-T for Refractory Graves' Disease
NCT07129642
A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)
NCT07286006
Allogeneic Anti-CD19/BCMA CAR-T for Refractory Graves' Disease
NCT07261345
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
NCT06727604
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BHV-1300
BHV-1300
BHV-1300 is delivered subcutaneously (SC)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BHV-1300
BHV-1300 is delivered subcutaneously (SC)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
2. History of treatment with radioactive iodine or thyroid surgery.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Biohaven Therapeutics Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site-103
South Gate, California, United States
Site-100
Miami, Florida, United States
Site-104
Columbus, Georgia, United States
Site-106
Houston, Texas, United States
Site-101
Houston, Texas, United States
Site-105
Shavano Park, Texas, United States
Site-004
Fitzroy, , Australia
Site-001
Kotara, , Australia
Site-003
Melbourne, , Australia
Site-008
Parkville, , Australia
Site-006
St Leonards, , Australia
Site-002
Torquay, , Australia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BHV1300-202
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.